Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950738 | 0.93 | PTGS2 (0.33) | PTGS2PTGS1KDM4EL3MBTL1NR3C2 | |
| SCHEMBL952307 | 0.92 | OPRL1 (0.34) | PTGS2PTGS1KDM4EL3MBTL1NR3C2 | |
| SCHEMBL954789 | 0.87 | KDM4E (0.35) | PTGS2PTGS1KDM4EL3MBTL1NR3C2 | |
| SCHEMBL952125 | 0.85 | PDPK1 (0.33) | PTGS2PTGS1KDM4EL3MBTL1NR3C2 | |
| SCHEMBL950412 | 0.84 | OPRL1 (0.35) | PTGS2PTGS1KDM4EL3MBTL1NR3C2 | |
| SCHEMBL952893 | 0.84 | KDM4E (0.33) | PTGS2PTGS1KDM4EL3MBTL1NR3C2 | |
| SCHEMBL951090 | 0.83 | PDPK1 (0.34) | PTGS2PTGS1KDM4EL3MBTL1NR3C2 | |
| SCHEMBL950060 | 0.81 | PTGS2 (0.36) | PTGS2PTGS1KDM4EL3MBTL1NR3C2 | |
| SCHEMBL952345 | 0.81 | KDM4E (0.37) | PTGS2PTGS1KDM4EL3MBTL1NR3C2 | |
| SCHEMBL950991 | 0.80 | HSD11B1 (0.36) | PTGS2PTGS1KDM4EL3MBTL1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968573-B2 | Hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20110071291-A1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | IKEGAMI HIROSHI | 2011-03-24 | — | — | US | disclosed |
| US-7867949-B2 | Hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-11 | — | — | US | disclosed |
| EP-2251336-A1 | Hydrazide compounds as intermediates of pesticides | Sumitomo Chemical Company, Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20090181956-A1 | Hydrazide Compound and Pesticidal Use of the Same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1937664-A1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | Sumitomo Chemical Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007043677-A9 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL CO (JP) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007043677-A1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071291-A1 | HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | ACHE, H1-2, H1-0 | PTGS2 801/4885PTGS1 880/4885KDM4E 1084/4885 |
| US-20090181956-A1 | Hydrazide Compound and Pesticidal Use of the Same | ACHE, DDT, CAT | PTGS2 903/4885PTGS1 744/4885KDM4E 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.